Tags: market
- Next GOLDMAN SACHS ON NEULAND LABS • Reiterate Buy, target price 12,975 from Rs 11,400 • FDA approval for Cobenfy is a key event • FY26 Xanomile estimates to be up 55-60% • CDMO business multiple raised to 40x from 37x GOLDMAN SACHS ON NEULAND LABS • Reiterate Buy, target price 12,975 from Rs 11,400 • FDA approval for Cobenfy is a key event • FY26 Xanomile estimates to be up 55-60% • CDMO business multiple raised to 40x from 37x
- Previous COMMODITY Market Updates 1 OCTOBER
Comments are closed.